Compare Amgen, Inc. (AMGN) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Unity Software Inc — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Unity Software Inc trades at $31.1 (market cap $13.48B). The key difference: Amgen, Inc. is far larger — about 14.5× Unity Software Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals.
| AMGN | U | |
|---|---|---|
Market Cap | $196.12B | $13.48B |
Sector | Health | Technology |
52-Week High | $388.16 | $49.47 |
52-Week Low | $271.18 | $17.13 |
Enterprise Value | $241.41B | $13.58B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Unity Software (U) trades at $30.89, up 0.52% today, with a bullish technical signal and strong analyst consensus. The stock shows improving revenue trends ($1.85B in 2025) and narrowing losses, though profitability remains negative. Recent news highlights momentum in AI advertising and cost restructuring, with Q2 2026 earnings expected on August 5, 2026.
Outlook: Growth potential exists through AI integration and margin expansion, but persistent net losses and high valuation multiples pose risks. Analyst price target of $36.50 suggests 18% upside, supported by bullish sentiment, yet investors must weigh execution risks against transformative opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
